Thus, exploring the synergistic effects of the combined therapy of Epi and ASOs against P-gp, MRP1, MRP2, and BCL-2/BCL-xL, may help us develop an effective strategy for multifunctional therapy of colon cancer. The gene discussed is BCL2L1; the disease is colonic neoplasm.